Impact of Genetic Variability on Cellular Pathways and Host-Microbiome Interactio

Information

  • Research Project
  • 9146329
  • ApplicationId
    9146329
  • Core Project Number
    U01DK062423
  • Full Project Number
    5U01DK062423-15
  • Serial Number
    062423
  • FOA Number
    RFA-DK-11-032
  • Sub Project Id
  • Project Start Date
    9/30/2002 - 22 years ago
  • Project End Date
    8/31/2017 - 7 years ago
  • Program Officer Name
    KARP, ROBERT W
  • Budget Start Date
    9/1/2016 - 8 years ago
  • Budget End Date
    8/31/2017 - 7 years ago
  • Fiscal Year
    2016
  • Support Year
    15
  • Suffix
  • Award Notice Date
    9/24/2016 - 8 years ago
Organizations

Impact of Genetic Variability on Cellular Pathways and Host-Microbiome Interactio

DESCRIPTION (provided by applicant): To date more than 100 genetic variants are known to be associated with inflammatory bowel disease (IBD). The majority of these have been identified by genome-wide association studies (GWAS). The individual Genetic Research Centers (GRCs) and the collective NIDDK IBD Genetics Consortium have successfully interacted for the last ten years to lead many of these discoveries. However, despite significant progress it is still unknown how the vast majority of these variants lead to IBD. Answering these questions is critical to advancing our knowledge of IBD pathophysiology. The University of Toronto GRC, led by Dr. Mark Silverberg, has made unique and substantial contributions in this field by virtue of its longstanding clinical and genetics expertise in IBD. Since 2002, Dr. Silverberg has established a very large, comprehensive registry of well characterized, longitudinally followed IBD patients at Mount Sinai Hospital in addition to accompanying biospecimens stored at his laboratory at the Samuel Lunenfeld Research Institute in order to facilitate research in IBD. Utilizing these resources, the UTGRC will advance the understanding of IBD pathophysiology in the following ways: (1) To identify gene expression profiles and pathways that will aid in classifying IBD and in revealing those that are mechanistically important in IBD pathophysiology. This will be accomplished by measuring gene expression profiles in the intestinal tissue of those affected and of healthy controls. (2) To evaluate the interaction between host genetic variation and the intestinal microbiome and determine how these changes affect the phenotypic expression of IBD. This will be accomplished by determining the composition of the microbial flora adherent to the intestinal tissue of those affected and of healthy controls. (3) To continue to work in an interactive fashion with the members of the Consortium to complete the discovery of all genetic variation associated with IBD and to advance our knowledge of the functional biology of such genetic variation such that we will effect change in the outcomes of individuals affected by IBD. This will be accomplished by ongoing clinical patient and biospecimen recruitment and by bringing significant clinical and scientific expertise to the Consortium team.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    U01
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
    401512
  • Indirect Cost Amount
    32121
  • Total Cost
    433633
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:433633\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZDK1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SINAI HEALTH SYSTEM
  • Organization Department
  • Organization DUNS
    208808949
  • Organization City
    TORONTO
  • Organization State
    ON
  • Organization Country
    CANADA
  • Organization Zip Code
    M5G 1X5
  • Organization District
    CANADA